Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:16:58 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Scandion Oncology - Resistance is Futile

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Scandion Oncology - Resistance is Futile

2021-11-29 10:00:00

Redeye provides an updated view on Scandion Oncology, following the company presenting its refocused strategy at its capital markets day and announcing PANTAX phase Ib readout’s delay into Q2-Q3 2022. Looking forward, we regard CORIST phase II part 2/3 and PANTAX phase Ib top-line data as the primary catalysts for Scandion in 2022.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/